Skip to main content

CytomX Therapeutics, Inc.

corporate_fare Company Profile

CytomX Therapeutics, Inc.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed CTMX - Latest Insights

CTMX
Apr 20, 2026, 4:15 PM EDT
Filing Type: PRE 14A
Importance Score:
9
CytomX Seeks Shareholder Approval to Double Authorized Common Stock, Signaling Significant Future Dilution
Sentiment: Negative
View Wiseek Article
CTMX
Mar 19, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
CytomX Therapeutics Closes $234.4M Public Offering at Premium to Market Price
Sentiment: Positive
View Wiseek Article
CTMX
Mar 16, 2026, 4:37 PM EDT
Filing Type: 424B5
Importance Score:
8
CytomX Therapeutics Details $250M Public Offering of Common Stock and Pre-Funded Warrants
Sentiment: Negative
View Wiseek Article
CTMX
Mar 16, 2026, 4:04 PM EDT
Source: GlobeNewswire
Importance Score:
9
CytomX Launches $250M Public Offering of Stock and Warrants
Sentiment: Negative
View Wiseek Article
CTMX
Mar 16, 2026, 4:01 PM EDT
Filing Type: S-3ASR
Importance Score:
7
CytomX Therapeutics Files Universal Shelf Registration to Enable Future Capital Raises
Sentiment: Neutral
View Wiseek Article
CTMX
Mar 16, 2026, 7:05 AM EDT
Source: Reuters
Importance Score:
8
CytomX Therapeutics Reports FY Revenue Miss, Falling $7.3M Short of Estimates
Sentiment: Negative
View Wiseek Article
CTMX
Mar 16, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
8
CytomX Therapeutics Reports Positive Phase 1 Varseta-M Data, Targets FDA Alignment for Registrational Trial, Alongside 2025 Financials
Sentiment: Positive
View Wiseek Article
CTMX
Mar 16, 2026, 7:01 AM EDT
Filing Type: 10-K
Importance Score:
8
CytomX Reports Steep Revenue Decline, Net Loss, and Major Partnership Terminations Amidst Highly Dilutive Capital Raise
Sentiment: Negative
View Wiseek Article
CTMX
Mar 13, 2026, 8:34 AM EDT
Source: Reuters
Importance Score:
7
CytomX Therapeutics Q4 Revenue Expected to Plunge 79%, Analysts Project 9-Cent Loss
Sentiment: Neutral
View Wiseek Article